Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
vTv TherapeuticsFRA:5VT0 +3.94%26 Equity-to-Asset is 0.90 as of Jun. 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 26/100. Among 1,416 Biotechnology companies, vTv Therapeutics ranks better than 82.63% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. vTv Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €68.25 Mil. vTv Therapeutics's Total Assets for the quarter that ended in Jun. 2026 was €76.03 Mil.
The historical rank and industry rank for vTv Therapeutics's Equity-to-Asset or its related term are showing as below:
FRA:5VT0'
s Equity-to-Asset Range Over the Past 10 Years
Min: -10.1 Med: -1.86 Max: 0.91
Current: 0.9
During the past 13 years, the highest Equity to Asset Ratio of vTv Therapeutics was 0.91. The lowest was -10.10. And the median was -1.86.
FRA:5VT0's Equity-to-Asset is ranked better than 82.63% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs FRA:5VT0: 0.90
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
vTv Therapeutics Equity-to-Asset Related Terms
vTv Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5VT0 vs VXRT, ENGN, SPRB: Equity-to-Asset Comparison
For the Biotechnology subindustry, vTv Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
vTv Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
vTv Therapeutics (FRA:5VT0) has a Equity-to-Asset of 0.90 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on vTv Therapeutics and its competitors. According to the industry distribution chart, vTv Therapeutics ranks #246 out of 1416 companies in the Biotechnology industry, placing it in the top 17.4%.
Is vTv Therapeutics' Equity-to-Asset too high?
vTv Therapeutics' current Equity-to-Asset is 0.90. The Biotechnology industry median Equity-to-Asset is 0.68. vTv Therapeutics' value of 0.90 is 32.4% above this industry median. Based on the distribution chart, vTv Therapeutics ranks #246 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, vTv Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Equity-to-Asset compare to VXRT and ENGN?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #246 out of 1416 companies for Equity-to-Asset. This places vTv Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. vTv Therapeutics' value of 0.90 is 32.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. vTv Therapeutics's current Equity-to-Asset of 0.90 is 32.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on vTv Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. vTv Therapeutics's current Equity-to-Asset is 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Equity-to-Asset of 0.90. The current Equity-to-Asset is 0.90 and 32.4% above the Biotechnology industry median of 0.68. vTv Therapeutics' overall GF Score™ is 26/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Equity-to-Asset is 0.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
26GF Score
Get the complete analysis for FRA:5VT0
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VT0 has been successfully added to your 
